Are you a Knight ADRC affiliated researcher with a news article you would like us to post?
Contact Us
Two Alzheimer’s drugs help patients live independently at home for longer periods (Links to an external site)
Lecanemab (Leqembi) and donanemab (Kisunla) could slow cognitive decline, but side effects exist.
Anti-amyloid treatments: Why we think they are worth it (Links to an external site)
Years of experience watching our patients progressively decline and die from complications of Alzheimer’s disease (AD) has strongly motivated us to provide newly approved anti-amyloid treatments to appropriate patients. Following detailed and personalized discussions of the potential risks and benefits of these treatments with patients and their families, almost 300 patients at our clinic have chosen to receive lecanemab infusions
Next-gen Alzheimer’s drugs extend independent living by month (Links to an external site)
New analysis recasts benefits of treatment in relation to day-to-day impacts on patients’ lives
International Alzheimer’s prevention trial in young adults begins (Links to an external site)
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
Can a Drug Prevent Alzheimer’s Disease Decades Before It Happens? (Links to an external site)
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.